Concrete is the most widely used material on earth after water, and we’re running out of a key ingredient. Widely used cement substitutes, known as supplementary cementitious materials (SCMs), have historically come from heavily polluting coal plants and iron blast furnaces. As those industrial processes are retired across the U.S. and Europe, SCM supply is […]

For decades, skincare has been driven by claims, trends, and trial-and-error. But what if we could actually measure how products impact the skin at the microbial and molecular level? That’s exactly what our SOSV portfolio company Sequential is doing. With a fresh $3.5 million Seed co-led by Sparkfood and Corundum Systems Biology (CSB), with participation […]

One of the most promising solutions to the surging energy demand lies beneath our feet: geothermal energy. But drilling to the super hot rock many miles down is a vexing technical challenge and is one reason why geothermal provides less than 1% of global electricity. Join us for a fireside chat on April 9, 2026 […]

Congrats to our SOSV portfolio company VALANX Biotech on its €3 million in new funding to advance its lead antibody-drug conjugate (ADC) program. The financing was led by Fournier-Majoie Foundation and FUJIFILM Corporation with participation from SOSV, XISTA Science Ventures, tecnet equity, Urs Spitz, and Skygene. The financing will enable pre-clinical development of VLX-ADC-001, a […]

Of all the languages an AI could master, without a doubt one of the hardest and most impactful is the genetic language of life itself.  So while our world is enthralled with the ability of LLMs to understand all human languages and programming languages, these LLMs also now understand the symbolic languages of math and musical […]

When SOSV and the New Jersey Economic Development Authority (NJEDA) announced a $50 million co-investment to build a new global headquarters for SOSV’s HAX in the heart of Newark in 2022, we knew the stakes were high. But HAX has just the right team to help early stage founders scale their product development and get to market, […]

📍 Broadcast live from our SOSV NY event space in Manhattan, SOSV Deep Tech LIVE is our monthly video podcast series exploring the frontiers of deep tech with leading founders, researchers, and technologists.  On the latest installment of SOSV Deep Tech Live (aired February 26, 2026), Dr. Susan Schofer (SOSV HAX) joined Dr. Barbara Burger to […]

Investors! Join HAX in New York on April 1 for Investor Showcase during New York Deep Tech Week featuring 20+ startups ranging from plasma physics to advanced chemistry to critical minerals, and more.

Back in 2018, Governor Phil Murphy set out to strengthen New Jersey as a home for breakthrough innovation by building new Strategic Innovation Centers (SIC), led by the New Jersey Economic Development Authority (NJEDA). Three years later, the NJEDA spotted an opportunity: an RFP from SOSV to select the global headquarters for its hard-tech program, HAX. […]

SOSV portfolio company and graduate of the IndieBio progrmam, Ten63 Therapeutics recently announced that it added strategic investment from new investors Chugai Venture Fund and the Gates Foundation, bringing the company’s total funding to over $45M. The company is an advanced AI drug-discovery company and with this increased funding they plan to fuel the advancement […]